News

Euclid Announces ABB Optical Group as Licensed Manufacturer and Distributor of Euclid Ortho-K Lenses

Euclid Vision Corporation (Euclid), a global leader in advanced orthokeratology (Ortho-K) lenses and proactive myopia management initiatives, is pleased to announce ABB Optical Group as a licensed manufacturer and distributor of the company’s Ortho-K lenses. ABB, known as the largest distributor of soft lenses in the United States, supplies nearly two-thirds of eye care professionals (ECPs) across the United States with optical products, services, and business solutions.

Given ABB’s reach, this new collaboration will provide greater access to Euclid’s clinically proven Ortho-K contact lenses to a much wider audience of ECPs. “The manufacturing and distribution arrangement capitalizes on the strengths of two leading companies in the specialty contact lens arena and manifests our shared vision of growing accessibility to myopia management products and services,” said Joseph Boorady, president and CEO, Euclid.

Euclid is the manufacturer of the Euclid Emerald® and Euclid MAX™ Ortho-K contact lenses, which are worn overnight and are designed to reshape the cornea, so patients wake up to clear vision. Euclid’s Ortho-K lenses have a unique design that yields an 87% first fit success¹ without requiring a trial set. ABB is well-equipped to support the manufacturing of Euclid’s lenses with their decades of gas permeable (GP) and custom soft lens manufacturing and specialty vision products distribution expertise.

“We are excited to work with Euclid and expand our licensed manufacturing, distribution, and myopia management product offerings with the addition of Euclid MAX lenses, a next generation Ortho-K product. Recognizing the continued rise of myopia as a serious eye-health issue, we are proud to bring an innovative Ortho-K design, which has the highest Dk of any US overnight Ortho-K brand, to our ABB customers.” said Aaron See, senior vice president of manufacturer partnerships, ABB.

Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050.² “Increased accessibility to Euclid’s Ortho-K lenses means ABB’s customers can broaden their myopia management initiatives and help more myopic children at a critical time in the myopia epidemic,” said Nitin Jain, chief commercialization officer, Euclid. “This trend presents both a clinical challenge and practice management opportunity for ECPs poised to best serve their myopic patients. Together with ABB, we can provide easier access to myopia management products to help mitigate the extent of this epidemic,” added Jain.

Visit the Euclid MAX landing page to get started.

Recent News

10/23/2024

Advancing Pharmaceutical Manufacturing in Central Virginia: The Success of the GO Virginia Grant

Activation Capital is proud to announce the successful closeout of a pivotal GO Virginia grant, addressing the urgent need to secure access to and reduce the costs of essential medicines. This grant laid the foundation for Central Virginia’s growth as a hub for advanced pharmaceutical manufacturing (APM) by leveraging the region’s strengths in advanced manufacturing,

10/22/2024

Caretaker Medical Awarded the Grand Prize in NIH RADx Tech for Maternal Health Challenge

Caretaker Medical, a digital health company focused on developing hemodynamic monitoring devices, today announced that it has been awarded the $525,000 grand prize in the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Technology for Maternal Health Challenge. The award recognizes Caretaker’s wireless, wearable wrist device, VitalStream, that can be used to monitor

10/22/2024

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces the further expansion of its on-going Netherton Syndrome (NS) clinical studies to include two additional international sites in the United Kingdom (UK). These sites, Great Ormond Street Hospital and St. Thomas’ Hospital,